MARKET

SRPT

SRPT

Sarepta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

85.25
+0.96
+1.14%
After Hours: 84.59 -0.66 -0.77% 19:59 02/25 EST
OPEN
83.65
PREV CLOSE
84.29
HIGH
89.49
LOW
81.58
VOLUME
3.12M
TURNOVER
--
52 WEEK HIGH
181.83
52 WEEK LOW
77.01
MARKET CAP
6.73B
P/E (TTM)
-10.8912
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sarepta stock rises after FDA approves biotech's Duchenne MD treatment
Shares of Sarepta Therapeutics Inc. undefined rose nearly 1% in late trading Thursday after the biotech company said the U.S. Food and Drug Administration...
marketwatch.com · 5h ago
Mizuho Securities Remains a Buy on Sarepta Therapeutics (SRPT)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Sarepta Therapeutics (SRPT) today and set a price target of $160.00. The company's shares
SmarterAnalyst · 5h ago
Sarepta shares up as FDA approves AMONDYS 45 for Duchenne Muscular Dystrophy
The FDA has approved AMONDYS 45 (casimersen) from Sarepta Therapeutics (SRPT) for the treatment of Duchenne Muscular Dystrophy in patients that have a mutation amendable to exon 45 skipping.Sarepta shares
Seekingalpha · 6h ago
BRIEF-Sarepta Therapeutics Announces FDA Approval Of Amondys 45 Injection As RNA Exon-Skipping Treatment for DMD
reuters.com · 6h ago
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45(TM) (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
-- AMONDYS 45 is Sarepta's third RNA exon-skipping treatment for DMD approved in the U.S. --
GlobeNewswire · 6h ago
Sarepta Wins FDA Approval for Amondys 45 for Rare Form of Duchenne Muscular Dystrophy
MT Newswires · 9h ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 12h ago
Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, Market Share, Application, Analysis, Regional Outlook, Growth, Trends and Forecasts 2020 - 2027 By Ameco Research
pune, India, Thu, 25 Feb 2021 04:57:42 / Comserve Inc. / -- Drugs for Duchenne Muscular Dystrophy (DMD) market to help players in achieving a strong market...
Comserve · 15h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRPT. Analyze the recent business situations of Sarepta through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 24 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRPT stock price target is 129.95 with a high estimate of 201.00 and a low estimate of 73.00.
EPS
Institutional Holdings
Institutions: 666
Institutional Holdings: 75.34M
% Owned: 95.47%
Shares Outstanding: 78.91M
TypeInstitutionsShares
Increased
120
2.94M
New
124
726.24K
Decreased
156
4.63M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.53%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Independent Director
M. Kathleen Behrens
President/Chief Executive Officer/Director
Douglas Ingram
Chief Financial Officer/Executive Vice President/Chief Accounting Officer
Ian Estepan
Executive Vice President
William Ciambrone
Executive Vice President
Alexander Cumbo
Executive Vice President
Gilmore O'Neill
Chief Scientific Officer
Louise Rodino-Klapac
General Counsel
Ryan Brown
Other
Dallan Murray
Independent Director
Richard Barry
Independent Director
Mary Gray
Independent Director
John Martin
Independent Director
Claude Nicaise
Independent Director
Hans Wigzell
  • Dividends
  • Splits
  • Insider Activity
No Data
About SRPT
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Webull offers kinds of Sarepta Therapeutics Inc stock information, including NASDAQ:SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.